Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 10/20 | 0.68 |
| ▸ | MAOA | P21397 | 4/20 | 0.41 |
| ▸ | MAOB | P27338 | 3/20 | 0.37 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30848924 | 0.89 | ERN1 (0.66) | ERN1MAOAMAOBCA9HSD17B10 | |
| SCHEMBL16197846 | 0.84 | ERN1 (0.58) | ERN1MAOAMAOBSORT1GAA | |
| SCHEMBL30848898 | 0.82 | ERN1 (0.47) | ERN1MAOBCA9GAAHSD17B10 | |
| SCHEMBL30848799 | 0.80 | ERN1 (1.00) | ERN1MAOAMAOBGAAHSD17B10 | |
| SCHEMBL16208775 | 0.80 | ERN1 (1.00) | ERN1MAOAMAOBGAAHSD17B10 | |
| SCHEMBL17601894 | 0.75 | ERN1 (0.49) | ERN1MAOAMAOBSORT1CA9 | |
| SCHEMBL14924884 | 0.74 | ERN1 (0.69) | ERN1MAOAMAOBGAAGFER | |
| SCHEMBL16197785 | 0.72 | ERN1 (0.56) | ERN1MAOAMAOBSORT1GAA | |
| SCHEMBL30848862 | 0.71 | ERN1 (0.46) | ERN1MAOBCA9GAAHSD17B10 | |
| SCHEMBL17601906 | 0.68 | ERN1 (0.47) | ERN1MAOAMAOBCA9GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240294487-A1 | INHIBITORS OF THE IRE-1/XBP-1 PATHWAY AND METHODS OF USING THEREOF | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2024-09-05 | — | — | US | disclosed |
| US-11945789-B2 | Inhibitors of the IRE-1/XBP-1 pathway and methods of using thereof | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2024-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11945789-B2 | Inhibitors of the IRE-1/XBP-1 pathway and methods of using thereof | XBP1, DDIT3, ERN1 | ERN1 3/4885MAOA 4317/4885MAOB 3832/4885 |
| US-20240294487-A1 | INHIBITORS OF THE IRE-1/XBP-1 PATHWAY AND METHODS OF USING THEREOF | XBP1, DDIT3, ERN1 | ERN1 3/4885MAOA 4317/4885MAOB 3832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.